Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vezocolmitide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Stuart Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ST-100 (vezocolmitide) is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen. It is under phase 3 clinical development for the treatment of Dry Eye D...
Brand Name : ST-100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 29, 2023
Lead Product(s) : Vezocolmitide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Stuart Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : OcuMension Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Brand Name : OT-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 22, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : OcuMension Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : OcuMension Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Brand Name : OT-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 07, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : OcuMension Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : OcuMension Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Brand Name : OT-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2021
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : OcuMension Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?